|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin.
|
30770953 |
2019 |
|
Amyloidosis
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
CSF NFL levels correlated with total tau (t-tau; <i>r</i> = 0.39 [95% CI: 0.27, 0.50]; <i>p</i> = 0.0001), phosphorylated tau (p-tau; <i>r</i> = 0.34 [95% CI: 0.19, 0.47]; <i>p</i> = 0.00001), and neurogranin (<i>r</i> = 0.25 [95% CI: 0.12, 0.37]; <i>p</i> = 0.001) but not with beta amyloid (Aβ) (<i>r</i> = 0.00 [95%CI: -0.13, 0.12]; <i>p</i> = 0.937).
|
31572170 |
2019 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
CSF neurogranin, YKL-40, and neurofilament light increased after the point of Aβ PET positivity.
|
31709776 |
2019 |
|
Amyloidosis
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We evaluated CSF amyloid-β (Aβ)42 and Aβ40, total (t)-tau, phosphorylated (p)-tau, total prion protein (t-PrP), and neurofilament light chain protein (NfL) in healthy controls (n = 50) and subjects with iNPH (n = 71), Alzheimer's disease (AD) (n = 60), and several other subtypes of dementia (n = 145).
|
30883350 |
2019 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
There was no interaction between Aβ42 and CSF NfL for risk of MCI.
|
30419087 |
2019 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
The examined predictors of Aβ status were demographics; cognitive tests; white matter lesions; apolipoprotein E (APOE); and plasma Aβ<sub>42</sub>/Aβ<sub>40</sub>, tau, and neurofilament light.
|
30365928 |
2019 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this respect, technical developments with ultrasensitive immunoassays and novel mass spectrometry techniques give promise of biomarkers to monitor brain amyloidosis (the Aβ42/40 or APP669-711/Aβ42 ratios) and neurodegeneration (tau and neurofilament light proteins) in plasma samples, but future studies are warranted to validate these promising results further.
|
30051512 |
2018 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
CSF biomarkers included total tau (t-tau) and neurofilament light chain (NfL) as a marker for neurodegeneration, phosphorylated tau (p-tau) as a marker for tau pathology, β-amyloid (Aβ) 38, 40, and 42 (Aβ<sub>38</sub>, Aβ<sub>40</sub>, and Aβ<sub>42</sub>) to monitor Aβ metabolism, and YKL-40 as a marker of neuroinflammation.
|
29237796 |
2018 |
|
Amyloidosis
|
0.090 |
Biomarker
|
disease |
BEFREE |
Altogether, our main findings suggest that Ng is strongly associated with Aβ pathology, whereas NFL is more unspecific.
|
28692877 |
2017 |